早期识别卡巴他赛所致严重中性粒细胞减少症风险患者
该研究汇总五项临床研究数据,采用群体药代动力学/药效学模型分析卡巴他赛全身暴露与中性粒细胞绝对计数(ANC)的关系。共纳入96例患者、1726个药代动力学样本和1081个ANC数据,发现输注开始后6小时卡巴他赛血浆浓度>4.96 ng/ml可预测严重中性粒细胞减少症(≥3级),灵敏度76%、特异度65%。
要点
- 输注开始后6小时卡巴他赛血浆浓度>4.96 ng/ml可预测严重中性粒细胞减少症。
- 该阈值识别严重中性粒细胞减少症的灵敏度为76%,特异度为65%。
- 若经前瞻性验证,高危患者可受益于预防性粒细胞集落刺激因子给药。
核心结论
- 早期卡巴他赛血浆浓度可预测严重中性粒细胞减少症。
- 实施所提出的药代动力学阈值可早期识别近76%的严重中性粒细胞减少症。
- 若经前瞻性验证,高危患者可受益于预防性粒细胞集落刺激因子给药,在治疗早期预防严重中性粒细胞减少症。
- 实施该阈值允许更少限制地使用25 mg/m2剂量,可能增加治疗获益。
研究设计与样本
- 汇总五项临床研究数据,使用NONMEM建立群体药代动力学/药效学模型,将患者特征和卡巴他赛全身暴露直接与ANC关联。
- 共纳入96例患者,共1726个药代动力学样本和1081个ANC数据。
- 使用受试者工作特征曲线确定预测严重中性粒细胞减少症(≥3级)的药代动力学阈值。
主要发现
- 群体药代动力学/药效学模型准确描述了卡巴他赛药代动力学和ANC。
- 输注开始后6小时卡巴他赛血浆浓度>4.96 ng/ml预测严重中性粒细胞减少症的灵敏度为76%,特异度为65%。
关键数值与推荐
- 卡巴他赛血浆浓度阈值:输注开始后6小时>4.96 ng/ml。
- 该阈值预测严重中性粒细胞减少症(≥3级)的灵敏度为76%,特异度为65%。
临床怎么用
- 测量卡巴他赛全身水平为临床医生提供了预防性刺激中性粒细胞生长的机会。
- 若经前瞻性验证,高危患者可受益于预防性粒细胞集落刺激因子给药。
- 实施该药代动力学阈值允许更少限制地使用25 mg/m2剂量,可能增加治疗获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cabazitaxel frequently causes severe neutropenia. A higher cabazitaxel systemic exposure is related to a lower nadir absolute neutrophil count (ANC). OBJECTIVE: To describe the effect of cabazitaxel systemic exposure on ANC by a population pharmacokinetic/pharmacodynamic (POP-PK/PD) model, and to identify patients at risk of severe neutropenia early in their treatment course using a PK threshold. DESIGN, SETTING, AND PARTICIPANTS: Data from five clinical studies were pooled to develop a POP-PK/PD model using NONMEM, linking both patient characteristics and cabazitaxel systemic exposure directly to ANC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A PK threshold, predictive of severe neutropenia (grade ≥3), was determined using a receiver operating characteristic curve. RESULTS AND LIMITATIONS: Ninety-six patients were included with a total of 1726 PK samples and 1081 ANCs. The POP-PK/PD model described both cabazitaxel PK and ANC accurately. A cabazitaxel plasma concentration of >4.96 ng/ml at 6 h after the start of infusion was found to be predictive of severe neutropenia, with a sensitivity of 76% and a specificity of 65%. CONCLUSIONS: Early cabazitaxel plasma levels are predictive of severe neutropenia. Implementation of the proposed PK threshold results in early identification of almost 76% of all severe neutropenias. If prospectively validated, patients at risk could benefit from prophylactic administration of granulocyte colony stimulating factors, preventing severe neutropenia in an early phase of treatment. Implementation of this threshold permits a less restricted use of the 25 mg/m2 dose, potentially increasing the therapeutic benefit. PATIENT SUMMARY: Treatment with cabazitaxel chemotherapy often causes neutropenia, leading to susceptibility to infections, which might be life threatening. We found that a systemic cabazitaxel concentration above 4.96 ng/ml 6 h after the start of infusion is predictive of the occurrence of severe neutropenia. Measurement of systemic cabazitaxel levels provides clinicians with the opportunity to prophylactically stimulate neutrophil growth.
引用
- Agema BC, Buck SAJ, Viskil M, et al. Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia. Eur Urol Oncol. 2023. PMID: 37925350. doi:10.1016/j.euo.2023.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。